1. Aromatase inactivation by 2-substituted derivatives of the suicide substrate androsta-1,4-diene-3,17-dione
- Author
-
Saki Ishikawa, Madoka Takahashi, Kouwa Yamashita, Wakako Handa, Mitsuteru Numazawa, and Hiromi Umeta
- Subjects
Diene ,medicine.drug_class ,Stereochemistry ,Placenta ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Clinical Biochemistry ,In Vitro Techniques ,Biochemistry ,Steroid ,Structure-Activity Relationship ,chemistry.chemical_compound ,Aromatase ,Endocrinology ,Pregnancy ,Microsomes ,medicine ,Humans ,Structure–activity relationship ,Molecular Biology ,Aromatase inhibitor ,biology ,Aromatase Inhibitors ,Cell Biology ,Androstadienes ,chemistry ,Estrogen ,Alkoxy group ,biology.protein ,Microsome ,Molecular Medicine ,Female - Abstract
To gain the structure-activity relationship of Delta(1)-androstenediones (Delta(1)-ADs) as mechanism-based inactivator of aromatase, series of 2-alkyl- and 2-alkoxy-substituted Delta(1)-ADs (6 and 9) as well as 2-bromo-Delta(1)-AD (14) were synthesized and tested. All of the inhibitors examined blocked aromatase in human placental microsomes in a competitive manner. In a series of 2-alkyl-Delta(1)-ADs (6), n-hexyl compound 6f was the most powerful inhibitor with an apparent K(i) value of 31 nM. The inhibitory activities of 2-alkoxy steroids 9 decreased in relation to length of the alkyl chain up to n-hexyloxy group (K(i): 95 nM for methoxy 9a). All of the alkyl steroids 6 along with the alkoxy steroid 9, except for the ethyl and n-propyl compounds 6b and 6c, caused a time-dependent inactivation of aromatase. The inactivation rates (k(inact): 0.020-0.084 min(-1)) were comparable to that of the parent compound Delta(1)-AD. The inactivation was prevented by the substrate AD, and no significant effect of l-cysteine on the inactivation was observed in each case. The results indicate that the 2-hexyl compound 6f act as the most powerful mechanism-based inactivator of aromatase among Delta(1)-AD analogs and may be submitted to the preclinical study in estrogen-dependent breast cancer.
- Published
- 2009
- Full Text
- View/download PDF